Preludedx
2 known investors
PreludeDx develops DCISionRT, a biomarker-based diagnostic test for ductal carcinoma in situ (DCIS) breast cancer that helps physicians predict a patient's recurrence risk and whether they would benefit from radiation therapy after breast-conserving surgery. It serves oncologists and breast cancer patients within the precision diagnostics field.
Investors Β· 2
Non-dilutive funding Β· 2 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $273.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Preludedx do?
- PreludeDx develops DCISionRT, a biomarker-based diagnostic test for ductal carcinoma in situ (DCIS) breast cancer that helps physicians predict a patient's recurrence risk and whether they would benefit from radiation therapy after breast-conserving surgery. It serves oncologists and breast cancer patients within the precision diagnostics field.
- Who are Preludedx's investors?
- Preludedx's investors include BlueStone Venture Partners, Evidity Health Capital.